
Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.
Advertisement
Articles by Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.

Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
3
Nondrug Therapies Ease Cough in Lung Cancer, Pulmonary Rehab Leads Pack
4
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MD
5